Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive cancers that have gene amplification of specific receptor tyrosine kinases (RTKs) including PDGFR as well as cKit. Here we report the effect of the c-Kit inhibitor imatinib and the selective c-Fms and c-Kit inhibitor PLX3397, both alone and in combination with the TORC1 inhibitor rapamycin, against MPNST cells. Our data strongly suggests that sustained inhibition of RTK signaling pathways by PLX3397 in vivo makes it superior to imatinib, even though the target specificity of the two drugs is comparable. Only PLX3397 could inhibit p-Fms in vivo resulting in a marked depletion of macrophages and significant tumor suppression in vivo. Furthermore, rapamycin was able to sustain tumor suppression by decreasing cell proliferation and promoting further macrophage depletion as part of the combination therapy. Our study can be translated into the development of PLX3397 and TORC1 inhibitor combination therapy for patients with MPNST. 
Introduction
Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue tumors with a very poor prognosis (1) . They are highly aggressive and therapeutically resistant tumors that arise in connective tissue surrounding peripheral nerves. MPNSTs occur in a subset of patients with Neurofibromatosis type 1 (NF1), an autosomal dominant genetic disorder (2, 3) . There is a 10% chance that patients with NF1 will develop MPNSTs in their lifetime (4, 5) . Despite advances in cancer treatment, MPNSTs typically remain fatal and there is an unmet need to develop new therapeutic strategies in this disease setting.
Growth factor dependent pathways driven specifically by receptor tyrosine kinases (RTKs) have been of particular interest due to their crucial role in tumor progression and survival. Targeting single or multiple RTK pathways using small molecule inhibitors is an attractive chemotherapeutic treatment option for blocking sarcoma cell growth. Such inhibitors have been used in sarcoma patients with some promising results (6, 7) . In addition to the RTKs, mTOR (mammalian target of Rapamycin) protein plays a key role in AKT activation and downstream survival signaling. Blocking RTK signaling pathways such as c-Kit and PDGFR using multitargeted inhibitors like imatinib has been used with some positive results in vitro in MPNSTs (8) (9) (10) . However, MPNSTs still remain one of the most challenging sarcoma subtypes to treat and novel therapeutic approaches are urgently needed to treat this disease.
MPNSTs have been shown to have gene amplification for receptor tyrosine kinases such as PDGFR as well as c-Kit (9, 11) . The role of c-Kit oncogenic mutations in gastro-intestinal Author Manuscript Published OnlineFirst on April 9, 2014; DOI: 10.1158/1078-0432.CCR- stromal tumors (GIST) is well established (12, 13) . PDGFRα has also been shown to be amplified in tumors and in cell lines from patients with MPNST. c-Kit was similarly amplified in four of the five tumors and patient derived cell lines. MPNSTs can also carry PDGFRα mutations. No mutations in c-Kit have been reported. Imatinib mesylate (Imatinib), an inhibitor of c-Kit and PDGFR, which is approved for the treatment of GIST, has been shown to be active in patients with plexiform neurofibromas, a slow-growing, chemotherapy resistant tumor that develops in patients with NF (14) . However, in clinical trials, response rates to imatinib in neurofibromatosis are only in the order of 17%, indicating that alternate signaling pathways must be involved in the growth and development of tumors associated with NF1 loss (14) . Though imatinib has never been formally tested in MPNST, it has been evaluated in patients affected by NF1 loss who developed GIST. Similar to MPNST patients, the overall prognosis of this patient population is poor, and the response to imatinib in NF1-associated GIST is very low (15) .
In this current study, we tested the multi-targeted tyrosine kinase inhibitor, PLX3397. PLX3397 selectively inhibits c-Fms and c-Kit receptor tyrosine kinases with biochemical IC 50 values of 0.02µM and 0.01µM respectively (16) . Recently it has been reported that macrophage infiltration of both mouse and human neurofibromas correlates with disease progression. Macrophages account for almost half of neurofibroma cells. In the Dhh-Cre/Nf1 mouse model of neurofibroma, PLX3397 has been shown to cause neurofibroma regressions and to block macrophage infiltration (17) . In this study, we elected to compare imatinib to PLX3397 against MPNST cells. Our studies indicate that PLX3397 is a superior in vivo kinase inhibitor and results in significantly greater suppression of tumor volume and macrophage depletion. 6 further enhances this effect. Findings from our studies suggest that PLX3397 in combination with an mTOR inhibitor is biologically active in MPNST and should be explored for future clinical development in patients with MPNSTs.
Research. 
Cell lines
MPNST and ST8814 cell lines have described previously (18) . GIST882 cell line has also been described previously (19) . Briefly, MPNST was derived from a patient with a high-grade peripheral nerve sheath tumor of the thigh. ST8814 was derived from a patient with NF1-associated MPNST of the thigh. Dr. Jonathan Fletcher, Dana Farber Cancer Institute, graciously supplied both these cell lines. In ST8814, a nonsense mutation (C910T) in codon 304 of exon 7 of NF1 has been reported (Y. Kloog, Tel Aviv University, Israel, personal communication to Dr. Schwartz). This is a pathogenic mutation leading to exon 7 skipping. These cell lines have been authenticated using Short Tandem Repeat DNA fingerprinting (20, 21) . MPNST cells were able to form tumors when injected in nude mice; however, we were unable to grow ST8814 tumors in mice. All the three cell lines were maintained in RPMI-1640 media containing 10% FBS (HyClone, Thermo Scientific). For serum starvation, cells were plated in RPMI-1640 media without FBS overnight and then treated with the drugs in RPMI-1640 media containing 10% FBS for the indicated time.
Cell viability assays
Cell viability assays were carried out with the Dojindo Molecular Technologies Kit per manufacturer's instructions. Briefly, 2,000 cells were plated in 96-well plates in RPMI media with 10% FBS and then treated with the indicated drugs the next day. Media was replaced with 100μL of media with 10% serum and 10% CCK-8 solution (Dojindo Molecular Technologies Kit). After 1 hour, the optical density was read at 450 nm using a Spectra Max 340 PC (Molecular Devices Corp.) to determine viability. Background values from negative control wells without cells were subtracted for final sample quantification. Data was plotted as % cell viability compared to DMSO (No Drug) control.
Western blots
Western blots were carried out as previously described (18) . Briefly, cell lysates were prepared by washing the cells once with sterile PBS followed by scraping in radioimmunoprecipitation assay (RIPA) lysis buffer. For xenograft tissues, lysates were prepared by cutting the snap frozen tumor tissue into a small piece and then grinding it in RIPA lysis buffer using sample grinding kit (GE Healthcare). Protein concentrations were measured using Bio-Rad protein assay dye (Bio-Rad) and equal amounts of protein (20 or 30μg) were loaded on 4% to 12% gradient gels (Invitrogen) and transferred to PVDF membrane (Immobilon, Millipore) or nitrocellulose membrane (0.45micron, Thermo Scientific) for the detection of phosphorylated c-Kit. After blocking with 5% milk, membranes were probed with primary antibodies overnight. Bound antibodies were detected with horseradish peroxidase secondary antibodies (GE Healthcare) and visualized by enhanced chemiluminescence reagent (GE Healthcare). Care and Use Committee-approved protocol, and institutional guidelines for the proper and humane use of animals were followed.
Analysis of tumor associated macrophages (TAMs): TAMs were isolated from control and drug treated xenograft samples (n=3 animals per group) as described previously (22) . Briefly, tumor cells were isolated by mincing the tumor in collagenase/DNAase in Hank's balanced salt solution (HBSS) followed by flow cytometric analysis using indicated antibodies. Data was plotted using Graph Pad Prism software with relevant population percentages plotted with ANOVA and t-test performed and indicated where appropriate.
Biostatistics
In vitro experiments were carried out at least 3 times unless otherwise indicated. Error bars shown in the graphs represent standard deviation. All the graphs were plotted using GraphPad Prism software. Statistical analyses were carried out using student's t-test with 95% CI. GIST cells, which harbor a c-Kit mutation and have a higher basal expression of p-Kit, were more susceptible to growth inhibition by PLX3397 than the MPNST cells. Western blot analysis using various concentrations of PLX3397 confirmed that p-Kit, a known target of the drug, was inhibited in all the three cell lines tested (Fig.1B) . In addition to p-Kit inhibition, AKT phosphorylation (p-AKTS473) was also inhibited ( whereas, MPNST cell lines showed higher basal levels of p-Fms (Y546) (Fig.1B) .
Phosphorylated c-Fms kinase is not down-regulated in MPNST cells in vitro
As shown in (Fig. 1C ). This result is consistent with the results obtained using western blot analysis (Fig.1B) . Total levels of c-Fms remained unchanged after the drug treatment in all the cell lines tested (Fig. 1D ).
PLX3397 and Imatinib inhibit MPNST cell proliferation and down-regulate downstream targets effectively in vitro
Since PLX3397 has recently been shown to impair tumor maintenance in mouse models of MPNSTs (17), we decided to focus our subsequent in vitro and in vivo experiments in the two MPNST cell lines. (25) . mTOR signaling has been shown to be particularly important for MPNST growth. However, mTOR inhibitors have shown minimal activity as single agents in sarcoma clinical studies (26, 27) .
PLX3397 does not inhibit TORC1
downstream targets including S6K and S6 ribosomal protein (S6) (Fig. 1B) . Therefore, we elected to test in the MPNST cells whether the combination of PLX3397 with the TORC1 inhibitor, rapamycin, could more effectively inhibit cell proliferation and to assess how this affected AKT and mTOR signaling. Results from the in vitro cell proliferation assay ( Fig. 2A) show that either PLX3397 or imatinib, when combined with rapamycin, were more efficient in inhibiting MPNST cell proliferation than any single agent drug treatment. Single agent treatment resulted in approximately 40-45% decrease in cell viability compared to no drug control, whereas, combination therapy resulted in approximately 70% inhibition of cell proliferation ( Fig.3 ). Many of the small molecular inhibitors that block RTK pathways such as sorafenib and lapatinib have been considered as cytostatic agents rather than cytotoxic drugs (29) . Fig.1A and 2A suggest that the effects of PLX3397 appear to be cytostatic rather than cytotoxic. To test this, we carried out flow cytometric cell cycle analysis after PLX3397 treatment either as single agent or in combination with rapamycin in MPNST and ST8814 cell lines. Treatment with PLX3397 but not rapamycin alone induced a G1-cell cycle arrest (Supplemental Fig.4A ), which was more pronounced when the two drugs were combined. Cyclin D1 down regulation has been shown to play a role in G1-cell cycle arrest in other cancer cell lines (30) . Western blot analysis after treatment with imatinib or PLX3397 alone induced significant down-regulation of cyclin D1 and a significant decrease in hyper-phosphorylated form of retinoblastoma protein (p-Rb) (Supplemental Fig.4B ).
Total levels of Rb and p53 remained unchanged. 
PLX3397 treatment results in sustained inhibition of RTKs and inhibits macrophage activation by blocking c-Fms
Imatinib and PLX3397 both have overlapping target specificity in vitro and were similarly effective in blocking in vitro cell proliferation in MPNST cells (Fig. 2A) . Therefore, we carried out mouse xenograft experiments to test whether the in vivo target inhibition profile of the two drugs was also similar. As shown in Fig. 3A and 3B , at the end of 3 week treatment, imatinib and rapamycin when used in combination resulted in enhanced suppression of tumor volume compared to either of the drugs alone (p<0.005). However, at completion of treatment (week 3) when xenograft lysates were analyzed by western blot, none of the target tyrosine kinases or TORC1 effectors (S6) were effectively down-regulated (Fig. 3C ). Since the animals were sacrificed approximately 24 hours after the last drug treatment, we hypothesized that the signaling pathways were re-activated in the 24 hours after the treatment. To test this hypothesis, we carried out a time course experiment in MPNST xenografts, wherein; the animals were sacrificed 8, 16 or 24 hours after the treatment on Day 1. As shown in Fig. 3D , imatinib alone inhibited p-Kit and p-PDGFRβ but not p-S6. Phosphorylation of S6K, a known mTORC1 target, either alone or in combination with imatinib, was down-regulated effectively confirming that the mTOR pathway is down-regulated by rapamycin in vivo. After 8 hours of treatment, p-Kit, p-PDGFRβ, p-AKT, and p-S6K were only inhibited in mice treated with imatinib in combination with rapamycin (Fig. 3D) . A stronger signal for PARP cleavage was seen with the combination of imatinib and rapamycin as compared to imatinib alone (Fig. 3D) . After 16 hours, p-Kit, p-PDGFRβ and p-AKT were re-activated even in animals treated with the imatinib and rapamycin combination suggesting that the signaling pathways are only transiently inhibited after this drug treatment (Fig. 3D) .
Next, we elected to repeat the mouse xenograft experiments using PLX3397. As shown (Fig. 4A and 4B), PLX3397 treatment resulted in significant tumor growth suppression when used either alone or in combination with rapamycin (p<0.005). As long as the animals were treated with PLX3397, the tumor was maintained at a significantly lower volume than vehicle control or rapamycin alone (Fig. 4A and 4B) . We did not observe any significant difference between PLX3397 alone versus PLX3397 and rapamycin combination in terms of tumor volume suppression ( Fig. 4A and 4B) . Therefore, we decided to test whether there was a difference between the tumor re-growth when the drug treatments were discontinued. The drug treatment was discontinued after 3 weeks, and the mice were monitored for increase in tumor volume for an additional 3 weeks. Surprisingly, tumors treated with PLX3397 alone grew back rapidly, whereas, mice treated with PLX3397 and rapamycin in combination showed a slower increase in tumor re-growth ( Fig. 4A and 4B ). Western blot analysis was carried out to determine whether PLX3397 inhibited p-Kit and p-PDGFRβ. Similar to imatinib treatment, the animals were sacrificed approximately 24 hours after the completion of treatment on week 3. However, unlike imatinib, PLX3397 was able to achieve sustained down regulation of p-Kit and p-PDGFRβ signaling, even after 24 hours after the last drug treatment. Furthermore, in contrast to the effect of PLX3397 in vitro, p-Fms was significantly inhibited in vivo (Fig. 4C ). We were unable to detect consistent expression levels of total S6 protein in these xenograft lysates; therefore, phosphorylation levels of S6 could not be determined. Nevertheless, p-AKT was inhibited significantly when animals were treated with PLX3397 alone and p-AKT was further downregulated when PLX3397 was used in combination with rapamycin (Fig. 4C) . Ki67 staining indicated a greater inhibition of cell proliferation with PLX3397 than with rapamycin (Supplemental Fig. 5A and B) . Treatment with PLX3397 and rapamycin resulted in even higher inhibition of cellular proliferation than when treated with PLX3397 alone (p<0.005). Xenograft lysates obtained from animals sacrificed 3 weeks after discontinuing the drug treatment showed that all the signaling pathways were re-activated when the drug treatments were discontinued (Fig. 4C, lanes 5 and 6) . Staining for CD31, a known endothelial cell marker, did not show any significant change after PLX3397 treatment compared to control group (Supplemental Fig.5C) As reported previously (31) rapamycin treatment alone caused a reduction in CD31 signal indicating reduced tumor vasculature (Supplemental Fig.5C ).
Ionized calcium-binding adapter molecule 1 or Iba-1 is a protein expressed specifically by macrophage/microglia cells and is involved tumor growth and maintenance mediated through cFms kinase (32, 33) . To test whether macrophage population was affected by imatinib and PLX3397 drug treatment, we carried out immunohistochemical staining to detect Iba-1. As shown in Fig. 5A and B, imatinib treatment alone did not affect Iba-1 signal as compared to vehicle control (p=0.365, not significant). However, Iba-1 signal was decreased significantly compared to vehicle control, when mice were treated with rapamycin either as a single agent or in combination with imatinib (p<0.05, Fig. 5A and B) .
Similar to previously published reports (17, 34) , PLX3397 significantly decreased macrophage population measured as Iba-1 signal (Fig. 5A and B, p<0.0001) . In contrast to imatinib, the effect of rapamycin and PLX3397, was greater than either agent alone (p<0.05). Next, we determined Iba-1 signal in tumor samples obtained 3 weeks after stopping the drug treatment. As expected, Iba-1 signal increased (Fig.5A and B versus 5C) when PLX3397 treatment was discontinued.
However, when compared to PLX3397 alone after discontinuation, Iba-1 signal remained 
Author Manuscript Published OnlineFirst on April 9, 2014; DOI: 10.1158/1078-0432.CCR- significantly suppressed at least for the first one week with the combination therapy of PLX3397 and rapamycin (Fig.5C and D) .
Macrophage depletion alone is not sufficient to suppress tumor growth in MPNST xenografts
To test whether the effects of PLX3397 on tumor growth suppression are mediated by inhibition of RTKs and/or macrophage depletion, we carried out xenograft studies by treating the animals using c-Fms specific drug (PLX5622) or a c-Fms specific antibody (AFS98) either alone or in combination with rapamycin and compared it against PLX3397. As observed earlier, PLX3397 either alone or in combination with rapamycin suppressed tumor growth significantly (Supplemental Figure 6A) . Western blot analysis showed down-regulation of target RTKs including p-Kit, p-PDGFRβ and p-Fms (Supplemental Fig.6B ). PLX5622, a c-Fms specific drug, showed moderate down-regulation of p-Fms (Y723) on western blot. Modest to no downregulation of other pathways including p-Kit, p-PDGFRβ and p-AKT was seen compared to PLX3397 (Supplemental Fig.6B ). As expected, c-Fms blockade by PLX5622 treatment resulted in macrophage depletion detected as reduced Iba-1 signal (Supplemental Fig.6C ). AFS98, a cFms specific antibody, treatment also showed moderate p-Fms down-regulation (Supplemental Fig.7A ) and as expected caused macrophage depletion detected as decreased percentage of live cells (Supplemental Fig.7B ). Though c-Fms blockade resulted in macrophage depletion (not comparable to PLX3397 however), it appeared that macrophage depletion alone was not sufficient to suppress tumor growth when xenografts were treated with PLX5622 or AFS98 alone (Supplemental Fig.6A and 7C ). Combination with rapamycin further enhanced macrophage depletion (Supplemental Fig.6C and   7B ) and also resulted in better tumor suppression (Supplemental Fig.6A and 7C ). Flow cytometric analysis showed that most of the tumor associated macrophage population (TAMs) was M2-like and rapamycin treatment alone caused M2-like TAMS to shift to more M1-like population (Supplemental Fig.8) . Such an effect of mTOR inhibition by rapamycin on macrophage polarization has been reported previously (35) . Sufficient numbers of macrophages could not be isolated from other treatment groups to carry out flow cytometric M1-like versus M2-like sorting. PLX3397 is a novel multi-targeted tyrosine kinase inhibitor that is selective for the M-CSF receptor kinase (c-Fms) and c-Kit. PLX3397 has recently been reported to have activity against breast cancer (16) , acute myeloid leukemia (41) as well as neurofibromas (17) . Although, it is a known c-Fms inhibitor, the exact mechanism of action of this drug, especially in MPNST, has not been reported. In this study, we tested the effects of the drug on two MPNST cell lines that were derived from patients with MPNST tumors of the thigh, one of which was NF1-associated (18) . Our results clearly demonstrate that PLX3397 inhibits in vitro cellular proliferation in MPNST cells. When we tested the activity of the drug in vitro using western blot analysis, we Imatinib has been shown to inhibit c-Fms phosphorylation at various therapeutic concentrations (23, 24) . Based on our in vitro data, the target specificity of imatinib and PLX3397 is highly overlapping. To test this specificity in vivo, we carried out MPNST mouse xenograft experiments using single agent or combination treatments. Interestingly, imatinib as a single agent or in combination with rapamycin was unable to maintain sustained inhibition of the target tyrosine kinases as well as AKT phosphorylation compared to PLX3397. PLX3397 was clearly superior in terms of sustained target inhibition compared to imatinib and also resulted in significant tumor volume suppression when the animals were treated with the drug alone or in combination with rapamycin.
c-Fms (M-CSF1R) kinase is involved in macrophage/microglial activation (33) . Iba-1 (Ionized calcium binding adapter molecule 1), is a macrophage/ microglia specific calcium-binding protein that has been shown to be involved in c-Fms mediated tumor growth (32) . Macrophages are typically divided into two types: classically activated or M1 and alternatively activated or M2 (44) . M1 macrophages are considered anti-tumorigenic, whereas, M2 macrophages are protumorigenic (45) and are required for tumor vascularization, invasion and development. Novel therapeutic strategies aimed at targeting M2 or Tumor Associated Macrophages (TAMs) are currently being pursued with much interest (46) . In a recent report (17) , mouse models of neurofibromas showed that PLX3397 was highly effective in inhibiting macrophages in 
rapamycin showed decreased macrophage re-infiltration when the drug treatments were discontinued. A recent study reported that tumor associated macrophages (M2) are dependent on mTOR signaling and inhibition of mTOR signaling by rapamycin can block tumor growth and angiogenesis by preventing monocyte differentiation into M2 macrophages (47) . Results from our Iba-1 staining and flow cytometric analysis indicated that rapamycin alone not only caused a decrease in macrophage population but also caused TAMs to shift from M2-like to more M1-like population partly explaining its potent anti-tumor effect in MPNST xenografts. Also, such a shift to M1-like population can possibly explain the observed lag time in tumor re-growth after PLX3397 and rapamycin treatment is discontinued compared to PLX3397 treatment alone. 30µg of RIPA lysates obtained using sample grinding kit (GE healthcare) from xenograft tissues at the end of 3 week treatment and 3 weeks after the drug treatment was stopped were loaded on SDS/PAGE and immunoblotted using indicated antibodies. 
